Home › Cancer types › Colorectal Cancer

Just diagnosed with colon or rectal cancer?

By the Cancer Clues team · Last updated 1 November 2026 · How we grade treatments

The honest numbers

Group statistics first, with the usual caveat: they describe populations, not you.

• About 159,000 US diagnoses expected in 2026 [1].
• Five-year relative survival (2016–2022 diagnoses): 65% overall — 91% localized, 75% regional, 17% after distant spread [1]. Even stage IV is sometimes curable when spread is limited to the liver or lungs and operable [4].
• The youth trend is real: 22% of diagnoses in 2022 were in people under 55 — double the share of 1995 — with rectal cancer driving much of the rise [2]. Nobody fully knows why yet; a 2025 study linked a childhood gut-bacteria toxin (colibactin) to early-onset tumors — an important clue, not yet a proven cause [3].

What's actually proven

• Colon and rectal cancer are treated differently. The rectum sits in a tight pelvis: radiation and specialized surgery matter there in ways they don't for most colon cancer [4][5].
• Surgery is the curative backbone for both, with chemotherapy added by stage and risk [4][5].
• One test changes everything: MSI/MMR. Every colorectal tumor should be tested. For the “MSI-high” minority (~15%), immunotherapy (pembrolizumab) beat chemotherapy as first treatment for metastatic disease in a major trial [6] — and see “What's new” for rectal cancer.
• Rectal cancer increasingly avoids the knife: after modern chemo-radiation (“total neoadjuvant therapy”), about half of patients in a leading trial kept their rectum under a strict “watch-and-wait” program, with survival similar to immediate surgery [7].

Stage-by-stage depth: NCI's patient guides for colon and rectal cancer [4] and the NCCN patient guidelines [5].

What people ask about (from our graded library)

• Turmeric / curcumin — the one genuinely interesting human signal is in this cancer: a 28-patient British trial added curcumin to chemotherapy for metastatic bowel cancer safely, with an intriguing but far-too-small survival hint. Still graded Unknown — and mind the chemo-interaction cautions on the page [8].
• Fasting around chemo and the keto diet — asked constantly here because “diet caused it” guilt runs strong. Honest answers: unproven for treating the cancer, and dangerous if you're losing weight. Diet quality matters for recovery; it is not chemotherapy.
• “Alkaline” diets and juice cleanses — no evidence, and aggressive versions cause the weight loss that genuinely worsens outcomes. Browse the full graded library.

Does the hospital matter?

For rectal cancer, clearly yes: studies find experienced, high-volume rectal surgeons have lower mortality and — what patients care about most — fewer permanent colostomies, because sphincter-preserving technique is a specialist skill [9]. For colon cancer the volume effect is weaker; a well-run multidisciplinary team matters more than a famous name. If you have rectal cancer, the two questions that earn their keep: “How many rectal resections does this surgeon do a year?” and “Am I a candidate for organ preservation (watch-and-wait)?” Second opinions before rectal surgery change plans often — we arrange them.

What's new (and real)

• The immunotherapy rectal story: in a trial of MSI-high rectal cancer, all 49 patients treated with dostarlimab alone saw their tumors disappear clinically — 96% still recurrence-free at two years — and in October 2026 the FDA approved this approach for locally advanced MSI-high rectal cancer: potentially no chemo, no radiation, no surgery for that small, testable group [10]. This is why the MSI test is non-negotiable.
• KRAS-targeted drugs arrived for a subset of metastatic disease (sotorasib + panitumumab, approved January 2025) [11].
• Blood-based follow-up (ctDNA) — promising for deciding who needs chemo after surgery (one trial halved chemo use without worse outcomes), but honestly still settling into practice; ask rather than assume [12].
• Screening now starts at 45 — colonoscopy every 10 years or a yearly stool test; a first blood-based screening test was approved in 2024 (less good at catching pre-cancers). Tell your family [13].

Questions for your oncologist (bring this list)

1. Has my tumor been tested for MSI/MMR (and, if metastatic, KRAS/BRAF)? What did it show?
2. Colon or rectal — and if rectal: am I a candidate for total neoadjuvant therapy and watch-and-wait?
3. If surgery: will it preserve the sphincter, and how many of these operations does the surgeon do yearly?
4. If stage IV: is my spread limited enough that surgery could still aim for cure?
5. Should my follow-up include ctDNA blood testing, and which trials fit me?

Common questions